Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Perisolv is a topical antiseptic cleaning gel composed of sodium hypochlorite activated with amino acids, which creates a chloramine-based formulation. Developed by Regedent AG and clinically evaluated in studies at the University of Witten/Herdecke, it is designed as an adjunctive therapy for the non-surgical treatment of periodontitis. The gel functions as a 'biofilm eraser' by chemically altering and softening the bacterial biofilm matrix within periodontal pockets. This action facilitates the more effective mechanical removal of bacteria and debris during subgingival scaling and root planing (SRP). In clinical practice, Perisolv is often applied subgingivally for 30–45 seconds prior to instrumentation and is frequently used in combination with cross-linked hyaluronic acid (such as hyaDent BG) to enhance tissue healing and pocket depth reduction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Perisolv.